Compazine Side Effects
Generic name: prochlorperazine
Note: This document contains side effect information about prochlorperazine. Some of the dosage forms listed on this page may not apply to the brand name Compazine.
Some side effects of Compazine may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to prochlorperazine: oral tablets, parenteral injection, rectal suppositories
Side effects include:
Drowsiness, dizziness, amenorrhea, blurred vision, skin reactions, hypotension.
For Healthcare Professionals
Applies to prochlorperazine: compounding powder, injectable solution, oral capsule extended release, oral syrup, oral tablet, rectal suppository
Nervous system side effects have been associated with the use of prochlorperazine (the active ingredient contained in Compazine) Most commonly, patients may experience sedation or dizziness. Extrapyramidal reactions may occur in less than 1% of patients receiving prochlorperazine. More commonly patients have reported akathisia and anxiety.
Sedation has been reported in up to 75% of patients treated with prochlorperazine. Extrapyramidal reactions have occasionally included torticollis, opisthotonos, carpopedal spasm, trismus, oculogyric crisis, and tongue protrusion. Dystonias usually resolve after neuroleptic discontinuation, but may require anticholinergic therapy if symptoms are severe.
Patients have also experienced pseudoparkinsonism reactions including mask-like facies, drooling, cogwheel rigidity, and shuffling gait. Pseudoparkinsonism symptoms may respond to judicious use of one or more of the following: benztropine, trihexyphenidyl, biperiden or diphenhydramine.
Occasionally, patients have experienced spasmodic contractions involving the mouth, difficulty swallowing, and pain in the jaw and neck. In a few severe cases, patients have experienced temporal mandibular joint subluxation.
Tardive dyskinesia, as with all phenothiazines, is possible with long-term use of prochlorperazine. Tardive dyskinesia involves involuntary, dyskinetic, repetitive movements and may be more common in elderly women receiving prochlorperazine. Tardive dyskinesia may be irreversible and is related to both the duration of therapy and the total amount of drug consumed.
Gastrointestinal side effects have included mild to moderate diarrhea.
Hepatic side effects have included the development of cholestasis (which has been chronic in at least two patients).
Hematologic side effects associated with prochlorperazine (the active ingredient contained in Compazine) have rarely included leukopenia and agranulocytosis.
Postmarketing safety experience suggests elderly patients may have an increased incidence of agranulocytosis compared to younger patients receiving prochlorperazine.
Cardiovascular side effects have occasionally included hypotension during intravenous administration of prochlorperazine (the active ingredient contained in Compazine)
Elderly patients may experience an increased sensitivity to the hypotensive effects of chlorperazine.
Other side effects have included cases of the neuroleptic malignant syndrome with other phenothiazines and in at least one patient treated with prochlorperazine (the active ingredient contained in Compazine)
Fever, altered consciousness, autonomic dysfunction, and muscle rigidity are the hallmarks of the neuroleptic malignant syndrome. The neuroleptic malignant syndrome is associated with a case fatality rate of about 20%. Immediate discontinuation of neuroleptic therapy and intensive monitoring and supportive care are indicated.
Dermatologic side effects associated with prochlorperazine (the active ingredient contained in Compazine) have included at least two cases of recurrent lip ulceration.
More Compazine resources
- Compazine Prescribing Information (FDA)
- Compazine MedFacts Consumer Leaflet (Wolters Kluwer)
- Compazine Concise Consumer Information (Cerner Multum)
- Prochlorperazine Prescribing Information (FDA)
- Prochlorperazine Professional Patient Advice (Wolters Kluwer)
- Prochlorperazine Monograph (AHFS DI)
- Compro Prescribing Information (FDA)
- Compro rectal Concise Consumer Information (Cerner Multum)
- Compro suppositories MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.